...
首页> 外文期刊>Journal of pharmaceutical sciences. >Comparison of X-ray Powder Diffraction and Solid-State Nuclear Magnetic Resonance in Estimating Crystalline Fraction of Tacrolimus in Sustained-Release Amorphous Solid Dispersion and Development of Discriminating Dissolution Method
【24h】

Comparison of X-ray Powder Diffraction and Solid-State Nuclear Magnetic Resonance in Estimating Crystalline Fraction of Tacrolimus in Sustained-Release Amorphous Solid Dispersion and Development of Discriminating Dissolution Method

机译:X射线粉末衍射和固态核磁共振估算他克莫司在持续释放非晶态固体分散体中晶体分数的比较及区分溶解方法的发展

获取原文
获取原文并翻译 | 示例

摘要

The focus of present investigation was to explore X-ray powder diffraction (XRPD) and solid-state nuclear magnetic resonance (ssNMR) techniques for amorphous and crystalline tacrolimus quantification in the sustained-release amorphous solid dispersion (ASD), and to propose discriminating dissolution method that can detect crystalline drug. The ASD and crystalline physical mixture was mixed in various proportions to make sample matrices containing 0%-100% crystalline-amorphous tacrolimus. Partial-least-square regression and principle component regression were applied to the spectral data. Dissolution of the ASD in the US FDA recommended dissolution medium with and without surfactant was performed. R-2 > 0.99 and slope was close to one for all the models. Root-mean-square of prediction, standard error of prediction, and bias were higher in ssNMR-based models when compared with XRPD data models. Dissolution of the ASD decreased with an increase in the crystalline tacrolimus in the formulations. Furthermore, detection of crystalline tacrolimus in the ASD was progressively masked with an increase in the surfactant level in the dissolution medium. XRPD and ssNMR can be used equally to quantitate the crystalline and amorphous fraction of tacrolimus in the ASD with good accuracy; however, ssNMR data collection time is excessively long, and minimum surfactant level in the dissolution medium maximizes detection of crystalline reversion in the formulation. (c) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:1777-1786, 2015
机译:本研究的重点是探索X射线粉末衍射(XRPD)和固态核磁共振(ssNMR)技术在持续释放无定形固体分散体(ASD)中进行无定形和结晶他克莫司定量分析的方法,并提出区分溶解的方法可以检测结晶药物的方法。将ASD和晶体物理混合物以各种比例混合,以制备包含0%-100%晶体-非晶态他克莫司的样品基质。偏最小二乘回归和主成分回归应用于光谱数据。在美国FDA建议的溶出介质中进行ASD的溶出,有或没有表面活性剂。 R-2> 0.99,所有模型的斜率均接近于1。与XRPD数据模型相比,在基于ssNMR的模型中预测的均方根,预测的标准误差和偏差更高。随着制剂中结晶他克莫司的增加,ASD的溶出度降低。此外,随着溶解介质中表面活性剂含量的增加,ASD中结晶他克莫司的检测逐渐被掩盖。 XRPD和ssNMR可以等效地准确定量ASD中他克莫司的结晶和无定形部分。但是,ssNMR数据收集时间过长,并且溶出介质中的最小表面活性剂含量使制剂中结晶回复的检测最大化。 (c)2015年,Wiley Periodicals,Inc.和美国药剂师协会J Pharm Sci 104:1777-1786,2015

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号